Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma

Fig. 2

Treatment response in patients treated with HH2853. (A) Best overall response by different dose levels in patients treated with HH2853. (B) Swimmer plot summarizing treatment duration and best response for patients on different doses of HH2853, with green arrows indicating ongoing patients. (C) Best overall response by pathological subtype in patients treated with HH2853

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us